胸主动脉腔内修复术在择期、症状性和破裂性胸主动脉疾病中的作用
院内死亡率为7.7%,急诊手术组显著高于择期组(14% vs 1.9%,P=0.001)。破裂组围术期死亡率显著高于症状组(25.6% vs 2.3%,P=0.002),而症状性与无症状患者围术期死亡率无差异。
要点
- TEVAR是胸主动脉疾病的有效治疗策略。
- 急诊TEVAR的院内死亡率和主要不良事件显著高于择期。
- 破裂性胸主动脉疾病围术期死亡率仍高,症状非破裂与无症状者早期结局相当。
核心结论
- TEVAR是胸主动脉疾病的有效治疗策略。
- 急诊修复破裂胸主动脉的围术期死亡率和并发症率仍高,但症状性非破裂与无症状患者早期结局相当。
研究设计与样本
- 单中心回顾性分析2010年至2016年所有连续接受TEVAR的患者,排除作为复杂胸腹修复一期手术的患者。
主要发现
- 治疗指征以夹层最多(n=92,44.2%;急性夹层40例,19.2%),其次为胸主动脉瘤(n=64,30.8%)、穿透性主动脉溃疡(n=37,17.8%)、壁内血肿(n=8,3.8%)、创伤性破裂(n=3,1.4%)及其他(n=4,1.8%)。
- 院内死亡率为7.7%,急诊组显著高于择期组(14% vs 1.9%,P=0.001)。
- 急诊手术更常发生主要不良临床事件(7.4% vs 26%,P=0.0003),尤其是截瘫(2.8% vs 10%,P=0.043)。
- 破裂组围术期死亡率显著高于症状组(25.6% vs 2.3%,P=0.002);症状性与无症状患者围术期死亡率无差异。
临床怎么用
- TEVAR可用于择期、症状性和破裂性胸主动脉疾病,但急诊尤其是破裂病例围术期风险高。
- 症状性非破裂患者早期结局与无症状者相当,可考虑积极TEVAR治疗。
局限性
- 单中心回顾性分析,结果可能受中心经验和患者选择偏倚影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Thoracic endovascular aortic repair (TEVAR) has emerged as a safe procedure in the treatment of a wide spectrum of descending thoracic aortic pathologies, with satisfactory results both in elective and urgent settings. We investigated the results of our elective, urgent and emergency TEVAR interventions. METHODS: A single-centre retrospective analysis of all consecutive patients undergoing TEVAR from 2010 to 2016 was performed. Primary end point of the study was early mortality, whereas the secondary end points included major complications according to the urgency of the procedure. The analysis was further conducted comparing symptomatic, asymptomatic and ruptured cases. RESULTS: Two hundred and eight patients were treated with TEVAR between January 2010 and April 2016 (mean age 67 ± 12 years, 142 men, 68.3%). Patients undergoing TEVAR as a first-stage procedure for complex thoraco-abdominal repair were excluded. The indication for treatment was a dissection in most cases (n = 92, 44.2%; acute dissection in 40 cases, 19.2%), followed by thoracic aneurysms (n = 64, 30.8%), penetrating aortic ulcers (n = 37, 17.8%), intramural haematomas (n = 8, 3.8%), traumatic ruptures (n = 3, 1.4%) and other indications (n = 4, 1.8%). One hundred and eight procedures were performed electively and 100 urgently. Forty-three patients were treated on an emergency bas for aortic rupture, 44 urgently for thoracic pain and 13 for acute ischaemic complications of aortic dissection or other indications. Ischaemic complications of dissection included 1 case of mesenteric ischaemia, 3 cases of acute renal failure, 4 cases of limb ischaemia and multiple ischaemic complications in 4 cases. Other causes of urgent TEVAR included 1 patient bleeding from a bronchial artery treated with TEVAR after several embolization attempts. In-hospital mortality was 7.7%, significantly higher in the urgent setting (14% vs 1.9%, P = 0.001). Urgent procedures were also more frequently associated with major adverse clinical events (7.4% vs 26%, P = 0.0003) and specifically with paraplegia (2.8% vs 10%, P = 0.043). Perioperative mortality was significantly higher in the ruptured group compared to the symptomatic group (25.6% vs 2.3%, P = 0.002). When the analysis was conducted to compare the symptomatic and the asymptomatic patients, no differences in terms of perioperative mortality were detected. CONCLUSIONS: TEVAR is an effective treatment strategy in thoracic aortic disease. Though emergency repair of the ruptured thoracic aorta still shows high rates of perioperative mortality and morbidity, symptomatic non-ruptured and asymptomatic patients have comparable early outcomes.
引用
- Fiorucci B, Kölbel T, Rohlffs F, et al. The role of thoracic endovascular repair in elective, symptomatic and ruptured thoracic aortic diseases. Eur J Cardiothorac Surg. 2019. PMID: 30768171. doi:10.1093/ejcts/ezy482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。